These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33986399)

  • 1. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
    Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
    J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
    Isono M; Okubo K; Asano T; Sato A
    PLoS One; 2022; 17(4):e0266476. PubMed ID: 35413091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
    Liu Y; Kwiatkowski DJ
    Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
    Oo ZY; Proctor M; Stevenson AJ; Nazareth D; Fernando M; Daignault SM; Lanagan C; Walpole S; Bonazzi V; Škalamera D; Snell C; Haass NK; Larsen JE; Gabrielli B
    Mol Oncol; 2019 Jul; 13(7):1503-1518. PubMed ID: 31044505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
    Montano R; Thompson R; Chung I; Hou H; Khan N; Eastman A
    BMC Cancer; 2013 Dec; 13():604. PubMed ID: 24359526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
    Al-Ejeh F; Pajic M; Shi W; Kalimutho M; Miranda M; Nagrial AM; Chou A; Biankin AV; Grimmond SM; ; Brown MP; Khanna KK
    Clin Cancer Res; 2014 Jun; 20(12):3187-97. PubMed ID: 24838526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
    Drápela S; Khirsariya P; van Weerden WM; Fedr R; Suchánková T; Búzová D; Červený J; Hampl A; Puhr M; Watson WR; Culig Z; Krejčí L; Paruch K; Souček K
    Mol Oncol; 2020 Oct; 14(10):2487-2503. PubMed ID: 32579780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
    Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
    Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
    Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
    Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
    Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
    Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
    Barnard D; Diaz HB; Burke T; Donoho G; Beckmann R; Jones B; Barda D; King C; Marshall M
    Invest New Drugs; 2016 Feb; 34(1):49-60. PubMed ID: 26612134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
    Jacob DA; Bahra M; Langrehr JM; Boas-Knoop S; Stefaniak R; Davis J; Schumacher G; Lippert S; Neumann UP
    J Gastroenterol Hepatol; 2007 May; 22(5):738-48. PubMed ID: 17444865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
    Dai CH; Wang Y; Chen P; Jiang Q; Lan T; Li MY; Su JY; Wu Y; Li J
    Sci Rep; 2017 Nov; 7(1):15031. PubMed ID: 29118324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Chk1 inhibitor MK-8776 increases the radiosensitivity of human triple-negative breast cancer by inhibiting autophagy.
    Zhou ZR; Yang ZZ; Wang SJ; Zhang L; Luo JR; Feng Y; Yu XL; Chen XX; Guo XM
    Acta Pharmacol Sin; 2017 Apr; 38(4):513-523. PubMed ID: 28042876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
    Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
    Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
    Boudny M; Zemanova J; Khirsariya P; Borsky M; Verner J; Cerna J; Oltova A; Seda V; Mraz M; Jaros J; Jaskova Z; Spunarova M; Brychtova Y; Soucek K; Drapela S; Kasparkova M; Mayer J; Paruch K; Trbusek M
    Haematologica; 2019 Dec; 104(12):2443-2455. PubMed ID: 30975914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
    Jamshed MB; Munir F; Shahid N; Sadiq U; Muhammad SA; Ghanem NB; Zhong H; Li X; Zhang Q
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G109-G119. PubMed ID: 31736340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanistic Distinctions between CHK1 and WEE1 Inhibition Guide the Scheduling of Triple Therapy with Gemcitabine.
    Koh SB; Wallez Y; Dunlop CR; Bernaldo de Quirós Fernández S; Bapiro TE; Richards FM; Jodrell DI
    Cancer Res; 2018 Jun; 78(11):3054-3066. PubMed ID: 29735549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
    Ma Y; Yu WD; Trump DL; Johnson CS
    Cancer; 2010 Jul; 116(13):3294-303. PubMed ID: 20564622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.